KR102166930B1 - Use of a peptide as a therapeutic agent for autoimmune disease or bone disease - Google Patents
Use of a peptide as a therapeutic agent for autoimmune disease or bone disease Download PDFInfo
- Publication number
- KR102166930B1 KR102166930B1 KR1020180110473A KR20180110473A KR102166930B1 KR 102166930 B1 KR102166930 B1 KR 102166930B1 KR 1020180110473 A KR1020180110473 A KR 1020180110473A KR 20180110473 A KR20180110473 A KR 20180110473A KR 102166930 B1 KR102166930 B1 KR 102166930B1
- Authority
- KR
- South Korea
- Prior art keywords
- group
- threonine
- proline
- cysteine
- serine
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 80
- 208000020084 Bone disease Diseases 0.000 title claims abstract description 25
- 239000003814 drug Substances 0.000 title abstract description 16
- 229940124597 therapeutic agent Drugs 0.000 title abstract description 10
- 208000023275 Autoimmune disease Diseases 0.000 title abstract description 8
- 206010003246 arthritis Diseases 0.000 claims abstract description 20
- 239000004480 active ingredient Substances 0.000 claims abstract description 12
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 31
- 239000004473 Threonine Substances 0.000 claims description 31
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 29
- 235000018417 cysteine Nutrition 0.000 claims description 28
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 28
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 26
- 150000001413 amino acids Chemical group 0.000 claims description 17
- 210000000988 bone and bone Anatomy 0.000 claims description 17
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 16
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 13
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 13
- 235000009582 asparagine Nutrition 0.000 claims description 13
- 229960001230 asparagine Drugs 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 235000013402 health food Nutrition 0.000 claims description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
- 208000001132 Osteoporosis Diseases 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 5
- 230000002757 inflammatory effect Effects 0.000 claims description 5
- 206010027476 Metastases Diseases 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 208000019664 bone resorption disease Diseases 0.000 claims description 4
- 230000009401 metastasis Effects 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 3
- 125000006239 protecting group Chemical group 0.000 claims description 3
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 208000037147 Hypercalcaemia Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- 208000016738 bone Paget disease Diseases 0.000 claims description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 2
- 230000000148 hypercalcaemia Effects 0.000 claims description 2
- 208000030915 hypercalcemia disease Diseases 0.000 claims description 2
- 208000037819 metastatic cancer Diseases 0.000 claims description 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 2
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 208000028169 periodontal disease Diseases 0.000 claims description 2
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 38
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 25
- 210000001744 T-lymphocyte Anatomy 0.000 abstract description 22
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract description 15
- 210000004027 cell Anatomy 0.000 abstract description 10
- 230000004069 differentiation Effects 0.000 abstract description 8
- 238000010171 animal model Methods 0.000 abstract description 4
- 206010071155 Autoimmune arthritis Diseases 0.000 abstract description 2
- 210000000068 Th17 cell Anatomy 0.000 description 12
- 210000002997 osteoclast Anatomy 0.000 description 12
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 210000000963 osteoblast Anatomy 0.000 description 9
- 238000010586 diagram Methods 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 8
- 238000010172 mouse model Methods 0.000 description 8
- 235000013930 proline Nutrition 0.000 description 8
- 235000004400 serine Nutrition 0.000 description 8
- 235000013355 food flavoring agent Nutrition 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 235000008521 threonine Nutrition 0.000 description 7
- CQTGBCFGAAYOCY-ZCRNMIQFSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-amino-5-oxopentanoyl]amino]-4-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-3-methyl-1-oxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@@H](NC(C)=O)C(C)C)C(C)C)[C@@H](C)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](C(C)C)C(N)=O CQTGBCFGAAYOCY-ZCRNMIQFSA-N 0.000 description 6
- 101100189913 Caenorhabditis elegans pept-1 gene Proteins 0.000 description 6
- 208000009386 Experimental Arthritis Diseases 0.000 description 6
- 101100243377 Mus musculus Pepd gene Proteins 0.000 description 6
- 230000024245 cell differentiation Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 108091033319 polynucleotide Proteins 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 108010088535 Pep-1 peptide Proteins 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- 235000004554 glutamine Nutrition 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 3
- 208000006386 Bone Resorption Diseases 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 3
- 101000883515 Homo sapiens Chitinase-3-like protein 1 Proteins 0.000 description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- -1 and the like Chemical class 0.000 description 3
- 210000000544 articulatio talocruralis Anatomy 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000024279 bone resorption Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 102000054350 human CHI3L1 Human genes 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102000003982 Parathyroid hormone Human genes 0.000 description 2
- 108090000445 Parathyroid hormone Proteins 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 210000002449 bone cell Anatomy 0.000 description 2
- 210000002805 bone matrix Anatomy 0.000 description 2
- 230000004097 bone metabolism Effects 0.000 description 2
- 230000010072 bone remodeling Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000199 parathyroid hormone Substances 0.000 description 2
- 229960001319 parathyroid hormone Drugs 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000004233 talus Anatomy 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 238000011763 DBA/1J (JAX™ mouse strain) Methods 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 206010023203 Joint destruction Diseases 0.000 description 1
- 206010023230 Joint stiffness Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- SNGZLPOXVRTNMB-LPEHRKFASA-N Pro-Ser-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CO)C(=O)N2CCC[C@@H]2C(=O)O SNGZLPOXVRTNMB-LPEHRKFASA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000014128 RANK Ligand Human genes 0.000 description 1
- 108010025832 RANK Ligand Proteins 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- DINQYZRMXGWWTG-GUBZILKMSA-N Ser-Pro-Pro Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 DINQYZRMXGWWTG-GUBZILKMSA-N 0.000 description 1
- XQJCEKXQUJQNNK-ZLUOBGJFSA-N Ser-Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O XQJCEKXQUJQNNK-ZLUOBGJFSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 210000000692 cap cell Anatomy 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000003108 foot joint Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 244000145841 kine Species 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 108010037248 lantibiotic Pep5 Proteins 0.000 description 1
- SRCAXTIBNLIRHU-JJKPAIEPSA-N lantibiotic pep5 Chemical compound N([C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N\C(=C/C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N\C(=C/C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N\C(=C(/C)S)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(O)=O)C(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](C)NC(=O)C(=O)CC SRCAXTIBNLIRHU-JJKPAIEPSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000007026 protein scission Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/306—Foods, ingredients or supplements having a functional effect on health having an effect on bone mass, e.g. osteoporosis prevention
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Polymers & Plastics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
본 발명은 치료제로서의 펩타이드의 용도에 관한 것으로, 본 발명의 펩타이드들은 자가면역질환에 관련된 T 세포(T cell)의 활성 및 Th17 세포(T helper 17 cell) 분화를 유의적으로 억제시키며, 관절염 동물모델에서 현저한 관절염 치료 및 개선 효과를 갖는 것을 확인하였으므로, 상기 펩타이드들은 골질환 치료제에 유효성분으로 이용될 수 있다.The present invention relates to the use of the peptide as a therapeutic agent, wherein the peptides of the present invention significantly inhibit the activity of T cells and differentiation of T helper 17 cells related to autoimmune diseases, and arthritis animal model Since it was confirmed that it has a remarkable effect on treating and improving arthritis, the peptides can be used as active ingredients in the treatment of bone diseases.
Description
본 발명은 골질환 치료제로서의 펩타이드의 용도에 관한 것으로, 보다 구체적으로 본 발명의 일반식 1로 기재되는 아미노산 서열로 구성된 펩타이드, 및 상기 펩타이드의 골다공증 등을 포함하는 골질환 치료 용도에 관한 것이다.The present invention relates to the use of a peptide as a therapeutic agent for bone diseases, and more specifically, to a peptide composed of an amino acid sequence represented by the
골 조직은 콜라겐, 당단백과 같은 세포외기질(extracellular substance)과 조골세포(osteoblast), 파골세포(osteoclast), 골세포 등 여러 종류의 세포들로 구성되어 있다. 특히, 조골세포(osteoblast)와 파골세포(osteoclast)의 상호 균형은 건강한 골격계 형성에 필수적이다. 즉, 골대사(bone metabolism)와 골재형성(bone remodeling)은 뼈 기질(bone matrix)를 만드는 조골세포(osteoblasts)와 뼈를 흡수하는 파골세포(osteoclasts) 사이의 균형적인 활동이 뼈의 항상성 유지에 중요하다.Bone tissue is composed of several types of cells, such as extracellular substances such as collagen and glycoprotein, and osteoblasts, osteoclasts, and bone cells. In particular, the mutual balance of osteoblasts and osteoclasts is essential for the formation of a healthy skeletal system. In other words, in bone metabolism and bone remodeling, a balanced activity between osteoblasts that make up the bone matrix and osteoclasts that absorb bones is important for maintaining bone homeostasis. Do.
골 조직은 콜라겐, 당단백과 같은 세포외기질(extracellular substance)과 조골세포(osteoblast), 파골세포(osteoclast), 골세포 등 여러 종류의 세포들로 구성되어 있다. 또한, 파골세포에 의한 골 흡수와 조골세포에 의한 새로운 골 기질 형성 및 무기질화 과정이 반복적으로 일어나는 대사기관으로, 조골세포의 활동으로 인한 골 형성이 파골세포의 활동으로 인한 골 흡수보다 많게 된다. 골의 재형성은 성장이 끝난 후 오래된 골을 제거하고 다시 새로운 골로 대치하는 과정으로, 부갑상선 호르몬(PTH), 칼시토닌, 에스트로겐 등과 같은 호르몬과 IGFI(insulin-like growth factor I) 등의 골조직에서 분비되는 다양한 성장인자, TNF-α(tumor necrosis factor-α) 등과 같은 사이토카인(cytokines)을 통해 조골세포와 파골세포의 활성 균형을 조절하며 항상성을 유지시킨다. 이러한 조골세포와 파골세포의 균형이 깨지는 경우 골다공증이나 관절염과 같은 질환이 유발하게 된다.Bone tissue is composed of several types of cells, such as extracellular substances such as collagen and glycoprotein, and osteoblasts, osteoclasts, and bone cells. In addition, as a metabolic organ in which bone resorption by osteoclasts and formation of new bone matrix and mineralization by osteoblasts occur repeatedly, bone formation due to the activity of osteoblasts is more than bone resorption due to the activity of osteoclasts. Bone remodeling is the process of removing old bone after growth is complete and replacing it with new bone.It is secreted by hormones such as parathyroid hormone (PTH), calcitonin, estrogen, and bone tissues such as insulin-like growth factor I (IGFI). Through various growth factors, cytokines such as TNF-α (tumor necrosis factor-α), it regulates the active balance of osteoblasts and osteoclasts and maintains homeostasis. If the balance between these osteoblasts and osteoclasts is broken, diseases such as osteoporosis or arthritis are caused.
특히, 조골세포와 파골세포의 균형이 깨지게 되면 파골세포에 의한 지나친 뼈의 파괴가 일어나게 되고 골다공증과 같은 질환으로 이어지게 되는 것이다. 이러한 파골세포는 골대사 과정에서 뼈의 흡수를 담당하는 특화된 세포로서 전구세포인 단핵구(monocyte)나 대식세포(macrophage)로부터 분화 프로그램을 통해서 형성된다. 또한, 파골세포는 αvβ3 인테그린(integrin) 등을 통해 골에 결합하며 산성 환경을 조성하는 한편 각종 콜라게네이즈(collagenase) 및 프로테아제(protease)를 분비하여 골 흡수(bone resorption)를 일으키므로, 이러한 파골세포를 억제가 골 질환 치료의 효과적인 방법이 될 수 있다.In particular, when the balance between osteoblasts and osteoclasts is broken, excessive bone destruction by osteoclasts occurs, leading to diseases such as osteoporosis. These osteoclasts are specialized cells responsible for bone absorption during bone metabolism, and are formed from progenitor cells such as monocytes or macrophages through a differentiation program. In addition, osteoclasts bind to bone through αvβ3 integrin, etc., create an acidic environment, and secrete various collagenases and proteases to cause bone resorption. Cell inhibition can be an effective method of treating bone disease.
한편, 최근 CD4+ T 세포 계통인 Th17 세포가 자가 면역질환의 염증 유발과 진행에 핵심적인 역할을 한다는 것이 밝혀지고 있으며, 이러한 Th17 세포의 중요성은 이 세포에서 분비된 IL-17이 자가면역질환과 직접적인 관계가 있는 것으로 밝혀짐으로서 더욱 커지고 있다.Meanwhile, it has been recently revealed that Th17 cells, the CD4+ T cell lineage, play a key role in the induction and progression of autoimmune diseases, and the importance of these Th17 cells is that IL-17 secreted from these cells is directly related to autoimmune diseases. It's getting bigger as it turns out to be related.
또한, Th17 세포는 골파괴의 주요 원인인 RANKL 및 여러 염증성 사이토카인을 유도하고(Chabaud and Miossec, 2001; Connell and McInnes, 2006), 이를 통해 염증 및 관절파괴 기전을 더욱더 활성화 하는 것으로 알려져 있다. 따라서, Th17 세포는 류마티스관절염을 포함하는 자가면역질환, 골질환에 관련된 신호전달 과정에서 핵심 병인 세포로 인정 받고 있으므로, Th17 세포 분화를 효과적으로 억제하는 후보물질의 발굴이 요구되고 있다.In addition, Th17 cells are known to induce RANKL and several inflammatory cytokines, which are the main causes of bone destruction (Chabaud and Miossec, 2001; Connell and McInnes, 2006), and further activate the mechanisms of inflammation and joint destruction through this. Therefore, Th17 cells are recognized as key pathogens in the signaling process related to autoimmune diseases and bone diseases, including rheumatoid arthritis, and thus, discovery of candidate substances that effectively inhibit Th17 cell differentiation is required.
이에, 본 발명자들은 치료제로서의 부작용을 최소화시키면서 유효한 치료 효과를 갖는 새로운 골질환 치료제를 개발하기 위해 노력한 결과, 본 발명에서 제조한 펩타이드가 골다공증을 포함하는 골질환 치료에 유용하게 사용될 수 있음을 밝힘으로써, 본 발명을 완성하였다.Accordingly, the present inventors have tried to develop a new therapeutic agent for bone diseases having an effective therapeutic effect while minimizing side effects as a therapeutic agent. As a result, by revealing that the peptide prepared in the present invention can be usefully used in the treatment of bone diseases including osteoporosis. , Completed the present invention.
본 발명의 목적은 골질환(bone disease) 예방 및 치료용 펩타이드를 제공하기 위한 것이다.It is an object of the present invention to provide a peptide for preventing and treating bone disease.
상기 목적을 달성하기 위하여, 본 발명은 In order to achieve the above object, the present invention
하기 서열번호 1로 기재되는 일반식 1의 아미노산 서열로 구성된 펩타이드, 및 상기 펩타이드를 유효성분으로 함유하는 골질환 예방 및 치료용 약학적 조성물, 또는 골질환 예방 및 개선용 건강식품을 제공한다.It provides a peptide consisting of the amino acid sequence of the
[일반식 1][General Formula 1]
(X1-X2-X3)n (X 1 -X 2 -X 3 ) n
상기 식에서, X1 내지 X3은 각각 프롤린(Proline; P), 세린(Serine; S), 트레오닌(Threonine; T), 글루타민(Glutamine; Q), 아스파라긴(Asparagine; N) 및 시스테인(Cysteine; C)으로 이루어진 군으로부터 선택되는 어느 하나이고, In the above formula, X 1 to X 3 are respectively Proline (P), Serine (S), Threonine (T), Glutamine (Q), Asparagine (N), and Cysteine (Cysteine; C). ) Is any one selected from the group consisting of,
n은 1 내지 10의 정수이며, 단 상기 일반식 1의 아미노산 서열이 서열번호 2로 기재되는 PSP를 포함하고, 동시에 n=1 내지 3 경우는 제외함. n is an integer of 1 to 10, provided that the amino acid sequence of the
본 발명의 펩타이드들은 자가면역질환에 관련된 T 세포(T cell)의 활성 및 Th17 세포(T helper 17 cell) 분화를 유의적으로 억제시키며, 관절염 동물모델에서 현저한 관절염 치료 및 개선 효과를 갖는 것을 확인하였으므로, 상기 펩타이드들은 골질환 치료제에 유효성분으로 이용될 수 있다.Since the peptides of the present invention significantly inhibit the activity of T cells and differentiation of
도 1은 본 발명의 합성 펩타이드에 의한 활성 T 세포 population(%)을 나타낸 도이다.
도 2는 본 발명의 합성 펩타이드에 의한 활성 T 세포 population(%)을 그래프로 나타낸 도이다.
도 3은 본 발명의 합성 펩타이드에 의한 T 세포 활성화 억제율(%)을 나타낸 도이다.
도 4는 본 발명의 합성 펩타이드에 Th17 세포 분화 억제 효능을 나타낸 도이다.
도 5는 콜라겐 유도 관절염 마우스 모델의 제조과정 및 본 발명에 따른 펩타이드의 투여 시기를 개략적으로 나타낸 모식도이다.
도 6은 본 발명의 Pep1 펩타이드의 관절염 개선 효과를 나타낸 도이다.
도 7은 본 발명의 Pep2 펩타이드의 관절염 개선 효과를 나타낸 도이다.
도 8은 본 발명의 Pep4 펩타이드의 관절염 개선 효과를 나타낸 도이다.
도 9는 본 발명의 Pep6 펩타이드의 관절염 개선 효과를 나타낸 도이다.1 is a diagram showing the active T cell population (%) by the synthetic peptide of the present invention.
2 is a graph showing the active T cell population (%) by the synthetic peptide of the present invention.
3 is a diagram showing the inhibition rate (%) of T cell activation by the synthetic peptide of the present invention.
4 is a diagram showing the effect of inhibiting Th17 cell differentiation on the synthetic peptide of the present invention.
Figure 5 is a schematic diagram showing the manufacturing process of the collagen-induced arthritis mouse model and the administration timing of the peptide according to the present invention.
6 is a diagram showing the effect of improving arthritis of the Pep1 peptide of the present invention.
7 is a diagram showing the effect of improving arthritis of the Pep2 peptide of the present invention.
8 is a diagram showing the effect of improving arthritis of the Pep4 peptide of the present invention.
9 is a diagram showing the effect of improving arthritis of the Pep6 peptide of the present invention.
이하, 본 발명의 용어는 하기와 같이 정의한다.Hereinafter, the terms of the present invention are defined as follows.
본 발명에서, 천연적으로 존재하는 아미노산에 대한 통상의 1문자 및 3문자 코드가 사용될 뿐만 아니라, Aib(α-아미노이소부티르산), Sar(N-methylglycine) 등과 같은 다른 아미노산에 대해 일반적으로 허용되는 3문자 코드가 사용된다. 또한 본 명세서에서 약어로 언급된 아미노산은 IUPAC-IUB 명명법에 따라 기재되었다.In the present invention, not only the usual 1-letter and 3-letter codes for naturally occurring amino acids are used, but also generally acceptable for other amino acids such as Aib (α-aminoisobutyric acid), Sar (N-methylglycine), etc. A 3-letter code is used. In addition, amino acids referred to as abbreviations herein have been described according to the IUPAC-IUB nomenclature.
본 발명의 “펩타이드(peptide)”는 아마이드 결합(또는 펩타이드 결합)으로 연결된 2개 이상의 아미노산으로 이루어진 폴리머를 의미하며, 본 발명의 목적상, 골질환 치료 효과를 가지는 펩타이드를 의미한다.The "peptide" of the present invention means a polymer consisting of two or more amino acids linked by an amide bond (or a peptide bond), and for the purposes of the present invention, it means a peptide having an effect of treating bone diseases.
본 발명의, "안정성"은 생체 내 단백질 절단효소의 공격으로부터 본 발명의 펩타이드를 보호하는 인 비보 안정성뿐만 아니라, 저장 안정성(예컨대, 상온 저장 안정성)도 의미한다.In the present invention, "stability" means not only in vivo stability that protects the peptide of the present invention from attack by protein cleavage enzymes in vivo, but also storage stability (eg, room temperature storage stability).
본 발명의, "예방"은 본 발명에 따른 약학적 조성물의 투여에 의해 질환을 억제시키거나 발병을 지연시키는 모든 행위를 의미한다.In the present invention, "prevention" refers to any action that suppresses or delays the onset of a disease by administration of the pharmaceutical composition according to the present invention.
본 발명의, "치료"는 본 발명에 따른 약학적 조성물의 투여에 의해 질환에 대한 증세가 호전되거나 이롭게 변경되는 모든 행위를 의미한다.In the present invention, "treatment" refers to any action in which symptoms of a disease are improved or advantageously changed by administration of the pharmaceutical composition according to the present invention.
본 발명의, "개체"는 질환의 치료를 필요로 하는 대상을 의미하며, 보다 구체적으로 인간 또는 비-인간인 영장류, 생쥐(mouse), 개, 고양이, 말 및 소 등의 포유류를 의미한다.In the present invention, "individual" refers to a subject in need of treatment of a disease, and more specifically refers to mammals such as human or non-human primates, mice, dogs, cats, horses and cattle.
본 발명의 "개선"이란 치료되는 상태와 관련된 파라미터, 예를 들면, 증상의 정도를 적어도 감소시키는 모든 행위를 의미한다.The term "improvement" of the present invention means any action that at least reduces the severity of a parameter associated with the condition being treated, for example a symptom.
이하, 본 발명을 보다 상세히 설명한다.Hereinafter, the present invention will be described in more detail.
본 발명은 The present invention
하기 서열번호 1로 기재되는 일반식 1의 아미노산 서열로 구성된 펩타이드, 및 상기 펩타이드를 유효성분으로 함유하는 골질환 예방 및 치료용 약학적 조성물을 제공한다:It provides a peptide consisting of the amino acid sequence of General Formula 1 represented by SEQ ID NO: 1, and a pharmaceutical composition for preventing and treating bone diseases containing the peptide as an active ingredient:
[일반식 1][General Formula 1]
(X1-X2-X3)n (X 1 -X 2 -X 3 ) n
상기 식에서, X1 내지 X3은 각각 프롤린(Proline; P), 세린(Serine; S), 트레오닌(Threonine; T), 글루타민(Glutamine; Q), 아스파라긴(Asparagine; N) 및 시스테인(Cysteine; C)으로 이루어진 군으로부터 선택되는 어느 하나이고, n은 1 내지 10의 정수이며, 단 상기 일반식 1의 아미노산 서열이 서열번호 2로 기재되는 PSP이면서, 동시에 n=1 내지 3 경우는 제외함.In the above formula, X 1 to X 3 are respectively Proline (P), Serine (S), Threonine (T), Glutamine (Q), Asparagine (N), and Cysteine (Cysteine; C). ) Is any one selected from the group consisting of, n is an integer of 1 to 10, provided that the amino acid sequence of Formula 1 is a PSP represented by SEQ ID NO: 2, and at the same time, n = 1 to 3 cases are excluded.
상기 펩타이드는 상기 일반식 1을 이용하여 다양한 펩타이드를 제조할 수 있으며, 이는 모두 본 발명에 포함된다. 또한, 상기 X1 내지 X3은 각각 프롤린(Proline; P), 세린(Serine; S) 및 트레오닌(Threonine; T)으로 이루어진 군으로부터 선택되는 어느 하나인 것이 바람직하고, 프롤린(Proline; P) 또는 세린(Serine; S)인 것이 보다 바람직하나 이에 한정되지 않는다.The peptides can be prepared by using the
또한, 상기 일반식에서 n은 1 내지 6의 정수인 것이 바람직하고, 1 내지 3인 것이 보다 바람직하다. Further, in the general formula, n is preferably an integer of 1 to 6, more preferably 1 to 3.
상기 본 발명의 펩타이드는 당해 분야에서 널리 공지된 다양한 방법으로 획득할 수 있다. 일례로서, 폴리뉴클레오타이드 재조합과 단백질 발현 시스템을 이용하여 제조하거나 펩타이드 합성과 같은 화학적 합성을 통하여 시험관 내에서 합성하는 방법, 및 무세포 단백질 합성법 등으로 제조될 수 있다.The peptide of the present invention can be obtained by various methods well known in the art. As an example, it may be prepared by using a polynucleotide recombination and protein expression system, or by a method for in vitro synthesis through chemical synthesis such as peptide synthesis, and a cell-free protein synthesis method.
또한, 보다 나은 화학적 안정성, 강화된 약리 특성(반감기, 흡수성, 역가, 효능 등), 변경된 특이성(예를 들어, 광범위한 생물학적 활성 스펙트럼), 감소된 항원성을 획득하기 위하여, 펩타이드의 N- 또는 C-말단에 보호기가 결합되어 있을 수 있다. 바람직하게, 상기 보호기는 아세틸기, 플루오레닐 메톡시 카르보닐기, 포르밀기, 팔미토일기, 미리스틸기, 스테아릴기 또는 폴리에틸렌 글리콜(PEG)일 수 있으나, 펩타이드의 개질, 특히 펩타이드의 안정성 증진시킬 수 있는 성분이라면, 제한없이 포함할 수 있다.In addition, in order to obtain better chemical stability, enhanced pharmacological properties (half-life, absorption, titer, efficacy, etc.), altered specificity (e.g., broad biological activity spectrum), reduced antigenicity, the N- or C of the peptide -A protective group may be attached to the end. Preferably, the protecting group may be an acetyl group, a fluorenyl methoxycarbonyl group, a formyl group, a palmitoyl group, a myristyl group, a stearyl group, or polyethylene glycol (PEG), but the modification of the peptide, especially the stability of the peptide Any component that can be included may be included without limitation.
상기 골질환은 관절염, 골다공증, 뼈전이암(bone metastatic cancer), 고형암 뼈전이, 고형암 뼈전이에 의한 근골격 합병증, 악성 종양으로 인한 과칼슘혈증, 다발성 골수종, 원발성(primary) 뼈 종양, 치주질환, 염증성 치조골 흡수질환, 염증성 뼈흡수 질환 및 파게트병(Paget's disease)으로 이루어진 군으로부터 선택되는 어느 하나 이상인 것이 바람직하나 이에 한정되지 않는다.The bone diseases include arthritis, osteoporosis, bone metastatic cancer, solid cancer bone metastasis, musculoskeletal complications due to solid cancer bone metastasis, hypercalcemia due to malignant tumor, multiple myeloma, primary bone tumor, periodontal disease, Any one or more selected from the group consisting of inflammatory alveolar bone resorption disease, inflammatory bone resorption disease, and Paget's disease is preferable, but is not limited thereto.
또한, 본 발명의 펩타이드를 코딩하는 폴리뉴클레오타이드를 사용해도 동일한 치료 효과를 나타낼 수 있으므로, 본 발명의 펩타이드를 코딩하는 폴리뉴클레오타이드도 본 발명에 포함되는 것이 자명한 사항이다. In addition, since the same therapeutic effect can be obtained even when the polynucleotide encoding the peptide of the present invention is used, it is obvious that the polynucleotide encoding the peptide of the present invention is also included in the present invention.
본 발명의 구체적인 실시예에서, 본 발명자들은 상기 일반식 1[(X1-X2-X3)n]을 이용하여 다양한 펩타이드를 제작하였다(표 1 참고).In a specific embodiment of the present invention, the present inventors produced various peptides using the general formula 1 [(X 1 -X 2 -X 3 ) n ] (see Table 1).
또한, 본 발명자들은 상기 펩타이드들의 T 세포 활성 억제 효과를 확인한 결과, 표 1의 펩타이드들은 평균 15 내지 25%까지 T 세포 활성을 유의적으로 억제하며, 이 중 임의적으로 선별한 펩타이드들의 T 세포 활성 억제 효과는 도 1 내지 도 3에 나타내었다(도 1 내도 도 3 참조).In addition, the present inventors confirmed the effect of inhibiting T cell activity of the peptides, the peptides in Table 1 significantly inhibited T cell activity by an average of 15 to 25%, of which randomly selected peptides inhibited T cell activity. The effect is shown in Figs. 1 to 3 (see Fig. 1 in Fig. 3).
또한, 본 발명자들은 상기 <실시예 1>에서 제작한 합성 펩타이드가 Th17 세포 분화를 억제시키는 효능을 확인한 결과, 본 발명의 펩타이드들은 Th17 세포 분화를 유의적으로 억제하는 것을 확인하였다(도 4 참조).In addition, the present inventors confirmed the efficacy of the synthetic peptide prepared in <Example 1> to inhibit Th17 cell differentiation, and confirmed that the peptides of the present invention significantly inhibited Th17 cell differentiation (see FIG. 4). .
아울러, 본 발명자들은 류마티스 관절염 동물모델을 제작한 후(도 5 참조), 본 발명의 펩타이드들의 치료 효과를 확인한 결과, 유의적인 관절염 개선 효과를 나타내고, 특히 양성대조군 MTX 대비 유사한 효능이 나타내는 것을 확인하였다(도 6 내지 도 9 참조). In addition, after the present inventors produced an animal model of rheumatoid arthritis (see FIG. 5), as a result of confirming the therapeutic effect of the peptides of the present invention, it was confirmed that a significant arthritis improvement effect was shown, and in particular, similar efficacy compared to the positive control MTX. (See Figs. 6 to 9).
따라서, 본 발명의 펩타이드들은 자가면역질환에 관련된 T 세포(T cell)의 활성 및 Th17 세포(T helper 17 cell) 분화를 유의적으로 억제시키며, 관절염 동물모델에서 현저한 관절염 치료 및 개선 효과를 갖는 것을 확인하였으므로, 상기 펩타이드들은 골질환 치료제에 유효성분으로 유용하게 사용될 수 있다.Therefore, the peptides of the present invention significantly inhibit the activity of T cells and differentiation of
한편, 본 발명의 펩타이드 또는 이를 코딩하는 폴리뉴클레오타이드는 콜로이드 현탁액, 분말, 식염수, 지질, 리포좀, 미소구체(microspheres), 또는 나노 구형입자와 같은 약학적으로 허용될 수 있는 담체에 운반될 수 있다. 이들은 운반 수단과 복합체를 형성하거나 관련될 수 있고, 지질, 리포좀, 미세입자, 금, 나노입자, 폴리머, 축합 반응제, 다당류, 폴리아미노산, 덴드리머, 사포닌, 흡착 증진 물질 또는 지방산과 같은 당업계에 공지된 운반 시스템을 사용하여 생체 내 운반될 수 있다.On the other hand, the peptide of the present invention or the polynucleotide encoding it may be transported in a pharmaceutically acceptable carrier such as a colloidal suspension, powder, saline, lipid, liposome, microspheres, or nano spherical particles. They can be complexed or associated with a vehicle and are known in the art such as lipids, liposomes, microparticles, gold, nanoparticles, polymers, condensation reagents, polysaccharides, polyamino acids, dendrimers, saponins, adsorption enhancing substances or fatty acids. It can be delivered in vivo using known delivery systems.
이 외에도, 약학적으로 허용되는 담체는 제제시 통상적으로 이용되는 락토스, 덱스트로스, 수크로스, 솔비톨, 만니톨, 전분, 아카시아, 고무, 인산칼슘, 알기네이트, 젤라틴, 규산 칼슘, 미세 결정성 셀룰로스, 폴리비닐 피로리돈, 셀룰로스, 물, 시럽, 메틸 셀룰로스, 메틸히드록시벤조에이트, 프로필 히드록시벤조에이트, 활석, 스테아르산 마그네슘 및 미네랄 오일 등을 포함할 수 있으나, 이에 한정되는 것은 아니다. 또한, 상기 성분들 이외에 윤활제, 습윤제, 감미제, 향미제, 유화제, 현탁제, 보존제 등을 추가로 포함할 수 있다.In addition, pharmaceutically acceptable carriers include lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia, rubber, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, which are commonly used in formulation. Polyvinyl pyrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, mineral oil, and the like, but are not limited thereto. In addition, a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, a preservative, etc. may be additionally included in addition to the above components.
본 발명의 약학적 조성물은 목적하는 방법에 따라 경구 투여하거나 비경구투여(예를 들어, 근육 내, 정맥 내, 복강 내, 피하, 피내, 또는 국소에 적용)할 수 있으며, 투여량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 시간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다.The pharmaceutical composition of the present invention can be administered orally or parenterally (for example, intramuscularly, intravenously, intraperitoneally, subcutaneously, intradermally, or topically applied) according to a desired method, and the dosage is It depends on the condition and weight, the degree of the disease, the form of the drug, the route of administration and the time, but may be appropriately selected by those skilled in the art.
본 발명의 약학적 조성물은 약학적으로 유효한 양으로 투여한다. 본 발명에 있어서 "약학적으로 유효한 양"은 의학적 치료에 적용 가능한 합리적인 수혜/위험 비율로 질환을 치료하기에 충분한 양을 의미하며, 유효 용량 수준은 환자의 질환의 종류, 중증도, 약물의 활성, 약물에 대한 민감도, 투여 시간, 투여 경로 및 배출 비율, 치료기간, 동시 사용되는 약물을 포함한 요소 및 기타 의학 분야에 잘 알려진 요소에 따라 결정될 수 있다. 본 발명에 다른 약학적 조성물은 개별 치료제로 투여하거나 다른 골질환 치료제와 병용하여 투여될 수 있고 종래의 골질환 치료제와는 동시에, 별도로, 또는 순차적으로 투여될 수 있으며, 단일 또는 다중 투여될 수 있다. 상기 요소들을 모두 고려하여 부작용 없이 최소한의 양으로 최대 효과를 얻을 수 있는 양을 투여하는 것이 중요하며, 이는 당업자에 의해 용이하게 결정될 수 있다.The pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount. In the present invention, "pharmaceutically effective amount" means an amount sufficient to treat a disease at a reasonable benefit/risk ratio applicable to medical treatment, and the effective dose level is the type, severity, drug activity of the patient, Sensitivity to drugs, time of administration, route of administration and rate of excretion, duration of treatment, factors including drugs used concurrently, and other factors well known in the medical field. The pharmaceutical composition according to the present invention may be administered as an individual therapeutic agent or administered in combination with another therapeutic agent for bone disease, and may be administered simultaneously, separately or sequentially with a conventional therapeutic agent for bone disease, and may be administered single or multiple. . It is important to administer an amount capable of obtaining the maximum effect in a minimum amount without side effects in consideration of all the above factors, and this can be easily determined by a person skilled in the art.
구체적으로 본 발명의 약학적 조성물의 유효량은 환자의 연령, 성별, 상태, 체중, 체내에 활성 성분의 흡수도, 불활성율, 배설 속도, 질병 종류, 병용되는 약물에 따라 달라질 수 있으며, 투여 경로, 비만의 중증도, 성별, 체중, 연령 등에 따라 증감될 수 있다.Specifically, the effective amount of the pharmaceutical composition of the present invention may vary depending on the patient's age, sex, condition, weight, absorption of the active ingredient in the body, inactivation rate, excretion rate, type of disease, and drugs used in combination, and the route of administration, Obesity may increase or decrease depending on the severity, sex, weight, and age.
아울러, 본 발명은 본 발명의 펩타이드 또는 이를 코딩하는 폴리뉴클레오타이드를 유효성분으로 함유하는 골질환 예방 및 개선용 건강식품을 제공한다.In addition, the present invention provides a health food for preventing and improving bone diseases containing the peptide of the present invention or a polynucleotide encoding the same as an active ingredient.
상기 건강식품은 질환의 예방 또는 개선을 위하여 해당 질환의 발병 단계 이전 또는 발병 후, 치료를 위한 약제와 동시에 또는 별개로서 사용될 수 있다.The health food may be used before or after the onset stage of the disease in order to prevent or improve the disease, and at the same time as or separately from the drug for treatment.
본 발명의 건강식품에서, 유효성분을 식품에 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 유효 성분의 혼합량은 그의 사용 목적(예방 또는 개선용)에 따라 적합하게 결정될 수 있다. 일반적으로, 식품 또는 음료의 제조시에 본 발명의 조성물은 원료에 대하여 바람직하게 15 중량% 이하, 바람직하게는 10 중량% 이하의 양으로 첨가될 수 있다. 그러나 건강 및 위생을 목적으로 하거나 또는 건강 조절을 목적으로 하는 장기간의 섭취의 경우에는 상기 양은 상기 범위 이하일 수 있다.In the health food of the present invention, the active ingredient may be added to the food as it is or may be used with other foods or food ingredients, and may be appropriately used according to a conventional method. The mixing amount of the active ingredient may be appropriately determined depending on the purpose of use (for prevention or improvement). In general, in the manufacture of food or beverage, the composition of the present invention may be added in an amount of preferably 15% by weight or less, preferably 10% by weight or less based on the raw material. However, in the case of long-term intake for the purpose of health and hygiene or for the purpose of health control, the amount may be less than the above range.
본 발명의 건강식품은 상기 유효성분을 함유하는 것 외에 특별한 제한없이 다른 성분들을 필수 성분으로서 함유할 수 있다. 예를 들면, 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스 등; 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당, 및 자일리톨, 소르비톨, 에리트리톨 등의 당 알코올일 수 있다. 상술한 것 이외의 향미제로서 천연 향미제(타우마틴, 스테비아 추출물(예를 들어, 레바우디오시드 A, 글리시르히진 등)) 및 합성 향미제(사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. 상기 천연 탄수화물의 비율은 당업자의 선택에 의해 적절하게 결정될 수 있다.In addition to containing the active ingredient, the health food of the present invention may contain other ingredients as essential ingredients without particular limitation. For example, as in ordinary beverages, various flavoring agents or natural carbohydrates may be included as additional ingredients. Examples of the above-described natural carbohydrates include monosaccharides such as glucose, fructose, and the like; Disaccharides such as maltose, sucrose, and the like; And polysaccharides, for example, conventional sugars such as dextrin, cyclodextrin, and the like, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those described above, natural flavoring agents (taumatin, stevia extract (eg, rebaudioside A, glycyrrhizin, etc.)) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. I can. The proportion of the natural carbohydrate can be appropriately determined by the choice of a person skilled in the art.
상기 외에 본 발명의 건강식품은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있으며, 이러한 첨가제의 비율 또한 당업자에 의해 적절히 선택될 수 있다.In addition to the above, the health food of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic flavors and natural flavoring agents, coloring agents and heavy weight agents (cheese, chocolate, etc.), pectic acid and salts thereof, alginic acid, and Salts thereof, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonates used in carbonated beverages, and the like may be contained. These components may be used independently or in combination, and the proportion of these additives may also be appropriately selected by those skilled in the art.
이하, 본 발명을 실시예 및 실험예에 의해 상세히 설명한다.Hereinafter, the present invention will be described in detail by examples and experimental examples.
단, 하기 실시예 및 실험예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예 및 실험예에 한정되는 것은 아니다.However, the following examples and experimental examples are merely illustrative of the present invention, and the contents of the present invention are not limited to the following examples and experimental examples.
<실시예 1> 펩타이드의 제작<Example 1> Preparation of peptide
하기 [일반식 1]을 기초로 다양한 펩타이드를 제작하였다. 이후, 고성능 액체크로마토그래피(SHIMADZU Prominence HPLC)를 이용하여 합성된 펩타이드 각각을 순수 분리하였으며, 컬럼은 Shiseido capcell pak C18 Column(4.6 × 50 mm)을 이용하였다. 또한, 질량분석기(HP 1100 series LC/MSD)를 이용하여, 합성된 펩타이드 각각의 질량을 확인하였다.Various peptides were prepared based on the following [General Formula 1]. Then, each of the synthesized peptides was purely separated using high-performance liquid chromatography (SHIMADZU Prominence HPLC), and a Shiseido capcell pak C18 Column (4.6 × 50 mm) was used as a column. In addition, mass spectrometry (HP 1100 series LC/MSD) was used to confirm the mass of each of the synthesized peptides.
[일반식 1][General Formula 1]
(X1-X2-X3)n (X 1 -X 2 -X 3 ) n
상기 식에서, X1 내지 X3은 각각 프롤린(Proline; P), 세린(Serine; S), 트레오닌(Threonine; T), 글루타민(Glutamine; Q), 아스파라긴(Asparagine; N) 및 시스테인(Cysteine; C)으로 이루어진 군으로부터 선택되는 어느 하나이고, In the above formula, X 1 to X 3 are respectively Proline (P), Serine (S), Threonine (T), Glutamine (Q), Asparagine (N), and Cysteine (Cysteine; C). ) Is any one selected from the group consisting of,
n은 1 내지 10의 정수이며, 단 상기 일반식 1의 아미노산 서열이 서열번호 2로 기재되는 PSP이고, 동시에 n=1 내지 3 경우는 제외함. n is an integer of 1 to 10, provided that the amino acid sequence of the
아울러, 상기 방법으로 합성된 펩타이드를 하기 표 1에 일부 나열하였다.In addition, some of the peptides synthesized by the above method are listed in Table 1 below.
<실험예 1> T 세포 활성 억제 효과 확인<Experimental Example 1> T cell activity inhibition effect confirmation
상기 <실시예 1>에서 제작한 합성 펩타이드의 T 세포 활성 억제 효능을 확인하기 위하여, 마우스의 림프절에서 추출한 T 세포를 사용하여 ex vivo 활성 억제 실험을 수행하였다.In order to confirm the T cell activity inhibition effect of the synthetic peptide prepared in <Example 1>, an ex vivo activity inhibition experiment was performed using T cells extracted from mouse lymph nodes.
구체적으로, 먼저, T 세포의 활성화를 유도하기 위하여 96 well plate에 CD3 항체를 coating하여 4℃에서 overnight 동안 incubation 하여 CD3항체가 붙어있는 96 well을 제작하였다. 그 후, 마우스에서 추출한 naive T 세포를 96 well plate에 1×105/well 씩 seeding 하고 상기 <실시예 1>에서 제작한 각 합성 펩타이드를 처리하여 18시간 동안 배양한 후 flow cytometry 방법으로 활성 T 세포의 population을 확인하였다. 이를 위해, 배양한 각각의 그룹에서 동일한 숫자의 세포를 collection 하고 PBS로 wash 과정을 거친 뒤, helper T 세포 마커인 rabbit anti-mouse CD4와 T 세포의 활성화 마커인 rabbit anti-mouse CD69 항체를 사용하여 staining 과정을 수행하였다. PBS로 washing한 뒤, CD4+CD69+ T 세포 population 을 분석하였다. Specifically, first, in order to induce activation of T cells, CD3 antibody was coated on a 96 well plate and incubated overnight at 4°C to prepare 96 wells with CD3 antibody attached. Thereafter, naive T cells extracted from mice were seeded at 1×10 5 /well in a 96 well plate, treated with each of the synthetic peptides prepared in Example 1, and cultured for 18 hours, and then activated T by flow cytometry. The population of cells was confirmed. To this end, the same number of cells were collected from each cultured group and washed with PBS, and then rabbit anti-mouse CD4, a helper T cell marker, and rabbit anti-mouse CD69 antibody, a T cell activation marker were used. The staining process was performed. After washing with PBS, the population of CD4+CD69+ T cells was analyzed.
그 결과, 상기 <실시예 1>에서 합성한 펩타이드는 평균 15 내지 25%까지 T 세포 활성을 유의적으로 억제하는 것을 확인하였다.As a result, it was confirmed that the peptide synthesized in <Example 1> significantly inhibited T cell activity by an average of 15 to 25%.
또한, 상기 <실시예 1>에서 합성한 펩타이드 중, 표 2에 나타낸 펩타이드의 T 세포 활성 억제효과에 대해서는 도 1 내지 도 3에 나타내었다.In addition, among the peptides synthesized in <Example 1>, the effects of the peptides shown in Table 2 on inhibiting T cell activity are shown in FIGS. 1 to 3.
구체적으로, 활성화를 유도하지 않은 그룹 (0.98%)에 비해 CD3 항체로 활성화 시킨 그룹에서 활성 T 세포가 74.8%로 증가하였고, 각 합성 펩타이드를 처리한 그룹에서는 55 ~ 62 % 까지 감소하는 것을 확인하였다. 또한, 각각의 합성 펩타이드의 활성 T 세포 억제율은 <실시예 1>에서 합성한 펩타이드와 동일하게 약 15% 에서 최대 25%임을 확인하였다.Specifically, it was confirmed that the active T cells increased to 74.8% in the group activated with CD3 antibody compared to the group that did not induce activation (0.98%), and decreased by 55 to 62% in the group treated with each synthetic peptide. . In addition, it was confirmed that the inhibition rate of active T cells of each of the synthetic peptides was about 15% to 25%, the same as the peptide synthesized in <Example 1>.
따라서, 본원발명의 합성 펩타이드는 T 세포 활성을 유의적으로 억제하여 골질환 치료에 사용될 수 있음을 확인하였다(도 1 내지 도 3).Therefore, it was confirmed that the synthetic peptide of the present invention can be used to treat bone diseases by significantly inhibiting T cell activity (FIGS. 1 to 3).
<실험예 2> Th 17 세포 분화 억제 효과 확인<Experimental Example 2>
상기 <실시예 1>에서 제작한 합성 펩타이드가 Th17 세포 분화를 억제시키는 효능을 확인하기 위하여, 마우스의 림프절에서 추출한 naive CD4+ T 세포에 TCR activation과 함께 IL-6 20 ng/ml과 TGF-beta 5 ng/ml을 처리하여 Th17 세포로 분화를 유도하였다. To confirm the efficacy of the synthetic peptide prepared in <Example 1> to inhibit Th17 cell differentiation, IL-6 20 ng/ml and TGF-
동시에 상기 <실험예 1>의 표 2에 개시된 펩타이드 3종 (Pep2, Pep3, Pep4) 을 10 ~ 1000 ng/ml의 농도로 각각 처리하였다. 그런 다음, 3일동안 incubation 한 뒤, CD4+IL-17+ T 세포 population 을 분석하였다. At the same time, the three peptides (Pep2, Pep3, Pep4) disclosed in Table 2 of <Experimental Example 1> were treated at a concentration of 10 to 1000 ng/ml, respectively. Then, after incubation for 3 days, the CD4+IL-17+ T cell population was analyzed.
그 결과, 도 4에 나타낸 바와 같이, Th17 세포로 분화를 유도하지 않은 그룹 (1.2%)에 비해 Th17 분화를 유도한 그룹에서 약 2.5배 증가하는 경향이 보였으며 (3.14%), Pep2, Pep3, Pep4 펩타이드를 각각 처리한 그룹에서는 분화를 유도하지 않은 그룹과 유사하게 Th17 세포의 비율이 감소하는 것을 확인하였다(도 4).As a result, as shown in Figure 4, compared to the group that did not induce differentiation into Th17 cells (1.2%), there was a tendency to increase about 2.5 times in the group inducing Th17 differentiation (3.14%), Pep2, Pep3, It was confirmed that the proportion of Th17 cells decreased in the group treated with the Pep4 peptide, similar to the group that did not induce differentiation (FIG. 4).
<실험예 3> Collagen-induced arthritis (CIA) mouse model을 이용한 류마티스 관절염 치료 효과 확인<Experimental Example 3> Confirmation of the treatment effect of rheumatoid arthritis using a Collagen-induced arthritis (CIA) mouse model
<3-1> 류마티스 관절염 마우스 모델의 제작<3-1> Preparation of rheumatoid arthritis mouse model
상기 <실시예 1>에서 제작한 펩타이드의 류마티스 관절염 개선 효과를 확인하기 위하여, 공지 문헌(Nat Protoc. 2007;2(5):1269-75.)을 참고하여 류마티스 관절염 마우스 모델을 제작하였다.In order to confirm the rheumatoid arthritis improvement effect of the peptide prepared in <Example 1>, a rheumatoid arthritis mouse model was prepared with reference to the publicly known literature (Nat Protoc. 2007;2(5):1269-75.).
구체적으로, CIA mouse model은 인간의 류마티스 관절염과 유사한 특징을 보이는 자가면역질환 관절염 모델로 류마티스 관절염 동물실험에서 가장 흔히 쓰이는 마우스 모델이다. CIA 마우스 모델은 먼저, 소의 제 2형 콜라겐(Bovine type II collagen, Chondrex, USA)과 프로인트 완전 보조제(Freund’s complete adjuvant, Chondrex, USA)를 1:1로 혼합하여 에멀젼화한 후, 에멀젼화된 콜라겐 용액 50 ul를 6주령의 DBA/1J 마우스 꼬리에 피내 주사하여 1차 면역(immunization) 시켰다. 1차 면역 후, 2주 째에 소의 제 2형 콜라겐과 프로인트 불완전 보조제(Freund’s incomplete adjuvant, Chondrex, USA)를 1:1로 혼합하여 에멀젼화한 후, 에멀젼화된 콜라겐 용액 50 ul를 마우스 꼬리에 피내 주사하여 2차 면역(boosting)을 유도하였다. 2차 면역 후, 다음날부터 1주일에 3회씩 각 펩타이드를 복강 투여하여 펩타이드의 류마티스 관절염 치료효과를 관찰하였다. 투여 펩타이드는 표 2에 개시된 펩타이드 4종(Pep1, Pep2, Pep4, Pep6)로 선정하였다(도 5).Specifically, the CIA mouse model is an autoimmune arthritis model showing characteristics similar to those of human rheumatoid arthritis, and is the most commonly used mouse model in rheumatoid arthritis animal experiments. The CIA mouse model was first emulsified by mixing bovine type II collagen (Chondrex, USA) and Freund's complete adjuvant (Chondrex, USA) in a 1:1 ratio, and then emulsified. 50 ul of collagen solution was injected intradermally into the tail of a 6-week-old DBA/1J mouse for primary immunization. After the first immunization, at the 2nd week, a 1:1 mixture of
<3-2> 류마티스 관절염 마우스 모델을 이용한 치료 효과 확인<3-2> Confirmation of treatment effect using a mouse model of rheumatoid arthritis
본 발명의 펩타이드 처리에 따른 류마티스 관절염 진행 추이를 살피고자, 시간의 경과에 따른 류마티스 관절염의 심화 정도를 류마티스 관절염 진행 지수로 평가하여 측정하였다.In order to examine the progression of rheumatoid arthritis according to the peptide treatment of the present invention, the degree of intensification of rheumatoid arthritis over time was evaluated and measured as the rheumatoid arthritis progression index.
구체적인 실험 조건에 대해서 알지 못하는 관찰자 두 명이 일주일에 세 번씩, 관절염 진행 정도를 평가하였다. 이때, 관절염 진행 지수는, 하기 표 2의 Rossoliniec 등에 의한 관절염 진행 평가 기준에 따라 각 다리당 0점 내지 4점으로 평가하여 총 0점 내지 16점(네 다리 합산)으로 나타내었으며, 이후, 두 명의 관찰자가 평가한 결과의 평균 값을 산출하여 관절염의 중증도를 수치화하였다. Two observers who were not aware of the specific experimental conditions evaluated the progression of arthritis three times a week. At this time, the arthritis progression index was evaluated as 0 to 4 points for each leg according to the criteria for arthritis progression evaluation by Rossoliniec in Table 2 below, and was expressed as a total of 0 to 16 points (sum of four legs). The average value of the results evaluated by the observer was calculated to quantify the severity of arthritis.
그 결과, 도 6 내지 도 9에 나타낸 바와 같이 정상 마우스(normal) 그룹과 비교하여, CIA를 유발한 마우스(Vehicle control; PBS)에서 관절염 스코어가 현저하게 증가하는 것을 알 수 있으며, 펩타이드 4종(Pep1, Pep2, Pep4, Pep6)을 각각 복강투여한 그룹에서 관절염 개선 효능이 나타나는 것을 확인하였다. 또한, 양성대조군 MTX 대비 유사한 효능이 나타내는 것을 확인하였다(도 6 내지 도 9). As a result, as shown in Figs. 6 to 9, it can be seen that the arthritis score is significantly increased in the mice (Vehicle control; PBS) inducing CIA, compared with the normal group, and 4 types of peptides ( Pep1, Pep2, Pep4, Pep6) was confirmed to show arthritis improvement efficacy in the group administered intraperitoneally. In addition, it was confirmed that similar efficacy compared to the positive control MTX was shown (FIGS. 6 to 9 ).
따라서, 본 발명의 펩타이드가 관절염을 포함하는 다양한 골질환 치료제로 사용할 수 있음을 확인하였다.Therefore, it was confirmed that the peptide of the present invention can be used as a therapeutic agent for various bone diseases including arthritis.
<110> Kine Sciences <120> Use of a peptide as a therapeutic agent for autoimmune disease or bone disease <130> PB2018-179 <150> KR 10-2017-0118947 <151> 2017-09-15 <160> 4 <170> KoPatentIn 3.0 <210> 1 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> PEPTIDE <220> <221> MISC_FEATURE <222> (1) <223> Xaa is Proline or Serine <220> <221> MISC_FEATURE <222> (2) <223> Xaa is Proline, Serine or Threonine <220> <221> MISC_FEATURE <222> (3) <223> Xaa is Proline, Serine, Threonine, Glutamine, Asparagine or Cysteine <400> 1 Xaa Xaa Xaa 1 <210> 2 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> PEPTIDE <400> 2 Pro Ser Pro 1 <210> 3 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Artificial Sequence <400> 3 Ser Pro Pro 1 <210> 4 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Artificial Sequence <400> 4 Ser Ser Ser 1 <110> Kine Sciences <120> Use of a peptide as a therapeutic agent for autoimmune disease or bone disease <130> PB2018-179 <150> KR 10-2017-0118947 <151> 2017-09-15 <160> 4 <170> KoPatentIn 3.0 <210> 1 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> PEPTIDE <220> <221> MISC_FEATURE <222> (1) <223> Xaa is Proline or Serine <220> <221> MISC_FEATURE <222> (2) <223> Xaa is Proline, Serine or Threonine <220> <221> MISC_FEATURE <222> (3) <223> Xaa is Proline, Serine, Threonine, Glutamine, Asparagine or Cysteine <400> 1 Xaa Xaa Xaa One <210> 2 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> PEPTIDE <400> 2 Pro Ser Pro One <210> 3 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Artificial Sequence <400> 3 Ser Pro Pro One <210> 4 <211> 3 <212> PRT <213> Artificial Sequence <220> <223> Artificial Sequence <400> 4 Ser Ser Ser One
Claims (9)
[일반식 1]
(X1-X2-X3)n
상기 식에서, X1은 프롤린(Proline; P) 및 세린(Serine; S)으로 이루어진 군으로부터 선택되는 어느 하나이고, X2는 프롤린(Proline; P), 세린(Serine; S) 및 트레오닌(Threonine; T)으로 이루어진 군으로부터 선택되는 어느 하나이며, X3은 프롤린(Proline; P), 세린(Serine; S), 트레오닌(Threonine; T), 글루타민(Glutamine; Q), 아스파라긴(Asparagine; N) 및 시스테인(Cysteine; C)으로 이루어진 군으로부터 선택되는 어느 하나이고;
n은 1 내지 7의 정수이며; 및
단 하기의 경우는 제외함:
i) X1 및 X2는 프롤린(Proline; P)이고, X3은 프롤린(Proline; P), 세린(Serine; S) 및 시스테인(Cysteine; C)으로 이루어진 군으로부터 선택되는 어느 하나이며, n은 1 내지 7의 정수인 경우;
ii) X1은 프롤린(Proline; P)이고, X2는 트레오닌(Threonine; T)이며, X3은 글루타민(Glutamine; Q), 아스파라긴(Asparagine; N) 및 시스테인(Cysteine; C)으로 이루어진 군으로부터 선택되는 어느 하나이며, n은 1 내지 7의 정수인 경우;
iii) X1은 세린(Serine; S)이고, X2는 프롤린(Proline; P), 세린(Serine; S) 및 트레오닌(Threonine; T)으로 이루어진 군으로부터 선택되는 어느 하나이며, X3은 트레오닌(Threonine; T), 글루타민(Glutamine; Q), 아스파라긴(Asparagine; N) 및 시스테인(Cysteine; C)으로 이루어진 군으로부터 선택되는 어느 하나이며, n은 1 내지 7의 정수인 경우; 및
iv) 상기 일반식 1의 아미노산 서열이 서열번호 2로 기재되는 PSP, 서열번호 3으로 기재되는 SPP 및 서열번호 4로 기재되는 SSS이며, n은 1 내지 7의 정수 경우는 제외함.
Peptide consisting of the amino acid sequence of general formula 1 represented by the following SEQ ID NO: 1.
[General Formula 1]
(X 1 -X 2 -X 3 ) n
In the above formula, X 1 is any one selected from the group consisting of proline (P) and serine (S), and X 2 is proline (P), serine (S), and threonine (Threonine; T) is any one selected from the group consisting of, X 3 is proline (P), serine (S), threonine (Threonine; T), glutamine (Glutamine; Q), asparagine (N), and Cysteine (Cysteine; C) is any one selected from the group consisting of;
n is an integer from 1 to 7; And
However, the following cases are excluded:
i) X 1 and X 2 are Proline (P), X 3 is any one selected from the group consisting of Proline (P), Serine (S) and Cysteine (C), and n Is an integer of 1 to 7;
ii) X 1 is Proline (P), X 2 is Threonine (T), X 3 is Glutamine (Q), Asparagine (N) and Cysteine (Cysteine; C) Any one selected from, and n is an integer of 1 to 7;
iii) X 1 is serine (S), X 2 is any one selected from the group consisting of Proline (P), Serine (S) and threonine (T), and X 3 is threonine (Threonine ; T), glutamine (Q), asparagine (N) and cysteine (Cysteine; C) any one selected from the group consisting of, and n is an integer of 1 to 7; And
iv) The amino acid sequence of Formula 1 is the PSP represented by SEQ ID NO: 2, the SPP represented by SEQ ID NO: 3, and the SSS represented by SEQ ID NO: 4, excluding the case where n is an integer of 1 to 7.
The peptide according to claim 1, wherein n is an integer of 1 to 6.
The peptide according to claim 1, wherein n is an integer of 1 to 3.
The method of claim 1, wherein the N- or C-terminus of the peptide is from the group consisting of an acetyl group, a fluorenylmethoxy carbonyl group, a formyl group, a palmitoyl group, a myristyl group, a stearyl group, and polyethylene glycol (PEG). Peptide, characterized in that bonded to the protecting group selected.
[일반식 1]
(X1-X2-X3)n
상기 식에서, X1은 프롤린(Proline; P) 및 세린(Serine; S)으로 이루어진 군으로부터 선택되는 어느 하나이고, X2는 프롤린(Proline; P), 세린(Serine; S) 및 트레오닌(Threonine; T)으로 이루어진 군으로부터 선택되는 어느 하나이며, X3은 프롤린(Proline; P), 세린(Serine; S), 트레오닌(Threonine; T), 글루타민(Glutamine; Q), 아스파라긴(Asparagine; N) 및 시스테인(Cysteine; C)으로 이루어진 군으로부터 선택되는 어느 하나이고;
n은 1 내지 7의 정수이며; 및
단 하기의 경우는 제외함:
i) X1 및 X2는 프롤린(Proline; P)이고, X3은 프롤린(Proline; P), 세린(Serine; S) 및 시스테인(Cysteine; C)으로 이루어진 군으로부터 선택되는 어느 하나이며, n은 1 내지 7의 정수인 경우;
ii) X1은 프롤린(Proline; P)이고, X2는 트레오닌(Threonine; T)이며, X3은 글루타민(Glutamine; Q), 아스파라긴(Asparagine; N) 및 시스테인(Cysteine; C)으로 이루어진 군으로부터 선택되는 어느 하나이며, n은 1 내지 7의 정수인 경우;
iii) X1은 세린(Serine; S)이고, X2는 프롤린(Proline; P), 세린(Serine; S) 및 트레오닌(Threonine; T)으로 이루어진 군으로부터 선택되는 어느 하나이며, X3은 트레오닌(Threonine; T), 글루타민(Glutamine; Q), 아스파라긴(Asparagine; N) 및 시스테인(Cysteine; C)으로 이루어진 군으로부터 선택되는 어느 하나이며, n은 1 내지 7의 정수인 경우; 및
iv) 상기 일반식 1의 아미노산 서열이 서열번호 2로 기재되는 PSP, 서열번호 3으로 기재되는 SPP 및 서열번호 4로 기재되는 SSS이며, n은 1 내지 7의 정수 경우는 제외함.
A pharmaceutical composition for the prevention and treatment of bone diseases containing as an active ingredient a peptide consisting of the amino acid sequence of the general formula 1 represented by the following SEQ ID NO:
[General Formula 1]
(X 1 -X 2 -X 3 ) n
In the above formula, X 1 is any one selected from the group consisting of proline (P) and serine (S), and X 2 is proline (P), serine (S), and threonine (Threonine; T) is any one selected from the group consisting of, X 3 is proline (P), serine (S), threonine (Threonine; T), glutamine (Glutamine; Q), asparagine (N), and Cysteine (Cysteine; C) is any one selected from the group consisting of;
n is an integer from 1 to 7; And
However, the following cases are excluded:
i) X 1 and X 2 are Proline (P), X 3 is any one selected from the group consisting of Proline (P), Serine (S) and Cysteine (C), and n Is an integer of 1 to 7;
ii) X 1 is proline (P), X 2 is threonine (T), and X 3 is glutamine (Q), asparagine (N) and cysteine (Cysteine; C). Any one selected from, and n is an integer of 1 to 7;
iii) X 1 is serine (S), X 2 is any one selected from the group consisting of Proline (P), Serine (S) and threonine (T), and X 3 is threonine (Threonine ; T), glutamine (Q), asparagine (N) and cysteine (Cysteine; C) any one selected from the group consisting of, and n is an integer of 1 to 7; And
iv) The amino acid sequence of Formula 1 is the PSP represented by SEQ ID NO: 2, the SPP represented by SEQ ID NO: 3, and the SSS represented by SEQ ID NO: 4, excluding the case where n is an integer of 1 to 7.
The method of claim 7, wherein the bone disease is arthritis, osteoporosis, bone metastatic cancer, solid cancer bone metastasis, musculoskeletal complications due to solid cancer bone metastasis, hypercalcemia due to malignant tumor, multiple myeloma, primary A pharmaceutical composition comprising at least one selected from the group consisting of bone tumors, periodontal disease, inflammatory alveolar bone resorption disease, inflammatory bone resorption disease, and Paget's disease.
[일반식 1]
(X1-X2-X3)n
상기 식에서, X1은 프롤린(Proline; P) 및 세린(Serine; S)으로 이루어진 군으로부터 선택되는 어느 하나이고, X2는 프롤린(Proline; P), 세린(Serine; S) 및 트레오닌(Threonine; T)으로 이루어진 군으로부터 선택되는 어느 하나이며, X3은 프롤린(Proline; P), 세린(Serine; S), 트레오닌(Threonine; T), 글루타민(Glutamine; Q), 아스파라긴(Asparagine; N) 및 시스테인(Cysteine; C)으로 이루어진 군으로부터 선택되는 어느 하나이고;
n은 1 내지 7의 정수이며; 및
단 하기의 경우는 제외함:
i) X1 및 X2는 프롤린(Proline; P)이고, X3은 프롤린(Proline; P), 세린(Serine; S) 및 시스테인(Cysteine; C)으로 이루어진 군으로부터 선택되는 어느 하나이며, n은 1 내지 7의 정수인 경우;
ii) X1은 프롤린(Proline; P)이고, X2는 트레오닌(Threonine; T)이며, X3은 글루타민(Glutamine; Q), 아스파라긴(Asparagine; N) 및 시스테인(Cysteine; C)으로 이루어진 군으로부터 선택되는 어느 하나이며, n은 1 내지 7의 정수인 경우;
iii) X1은 세린(Serine; S)이고, X2는 프롤린(Proline; P), 세린(Serine; S) 및 트레오닌(Threonine; T)으로 이루어진 군으로부터 선택되는 어느 하나이며, X3은 트레오닌(Threonine; T), 글루타민(Glutamine; Q), 아스파라긴(Asparagine; N) 및 시스테인(Cysteine; C)으로 이루어진 군으로부터 선택되는 어느 하나이며, n은 1 내지 7의 정수인 경우; 및
iv) 상기 일반식 1의 아미노산 서열이 서열번호 2로 기재되는 PSP, 서열번호 3으로 기재되는 SPP 및 서열번호 4로 기재되는 SSS이며, n은 1 내지 7의 정수 경우는 제외함.
Health food for preventing and improving bone diseases containing a peptide consisting of the amino acid sequence of General Formula 1 represented by the following SEQ ID NO: 1 as an active ingredient:
[General Formula 1]
(X 1 -X 2 -X 3 ) n
In the above formula, X 1 is any one selected from the group consisting of proline (P) and serine (S), and X 2 is proline (P), serine (S), and threonine (Threonine; T) is any one selected from the group consisting of, X 3 is proline (P), serine (S), threonine (Threonine; T), glutamine (Glutamine; Q), asparagine (N), and Cysteine (Cysteine; C) is any one selected from the group consisting of;
n is an integer from 1 to 7; And
However, the following cases are excluded:
i) X 1 and X 2 are Proline (P), X 3 is any one selected from the group consisting of Proline (P), Serine (S) and Cysteine (C), and n Is an integer of 1 to 7;
ii) X 1 is proline (P), X 2 is threonine (T), and X 3 is glutamine (Q), asparagine (N) and cysteine (Cysteine; C). Any one selected from, and n is an integer of 1 to 7;
iii) X 1 is serine (S), X 2 is any one selected from the group consisting of Proline (P), Serine (S) and threonine (T), and X 3 is threonine (Threonine ; T), glutamine (Q), asparagine (N) and cysteine (Cysteine; C) any one selected from the group consisting of, and n is an integer of 1 to 7; And
iv) The amino acid sequence of Formula 1 is the PSP represented by SEQ ID NO: 2, the SPP represented by SEQ ID NO: 3, and the SSS represented by SEQ ID NO: 4, excluding the case where n is an integer of 1 to 7.
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020515231A JP7122018B2 (en) | 2017-09-15 | 2018-09-14 | Use of Peptides as Therapeutic Agents for Autoimmune and Bone Diseases |
| PCT/KR2018/010873 WO2019054808A2 (en) | 2017-09-15 | 2018-09-14 | Use of peptides as therapeutic agent for autoimmune diseases and bone diseases |
| US16/646,069 US11629169B2 (en) | 2017-09-15 | 2018-09-14 | Use of peptides as therapeutic agent for autoimmune diseases and bone diseases |
| CA3075607A CA3075607A1 (en) | 2017-09-15 | 2018-09-14 | Use of peptides as therapeutic agent for autoimmune diseases and bone diseases |
| AU2018332486A AU2018332486B2 (en) | 2017-09-15 | 2018-09-14 | Use of peptides as therapeutic agent for autoimmune diseases and bone diseases |
| US18/174,730 US20230234985A1 (en) | 2017-09-15 | 2023-02-27 | Use of peptides as therapeutic agent for autoimmune diseases and bone diseases |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20170118947 | 2017-09-15 | ||
| KR1020170118947 | 2017-09-15 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20190031182A KR20190031182A (en) | 2019-03-25 |
| KR102166930B1 true KR102166930B1 (en) | 2020-10-19 |
Family
ID=65907963
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020180110473A KR102166930B1 (en) | 2017-09-15 | 2018-09-14 | Use of a peptide as a therapeutic agent for autoimmune disease or bone disease |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102166930B1 (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140087997A1 (en) * | 2011-05-11 | 2014-03-27 | Technion Research & Development Foundtion Limited | Anti-microbial peptides and uses of same |
| WO2016204841A1 (en) * | 2015-06-17 | 2016-12-22 | Avon Products, Inc. | Peptides and their use in the treatment of skin |
-
2018
- 2018-09-14 KR KR1020180110473A patent/KR102166930B1/en active IP Right Grant
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140087997A1 (en) * | 2011-05-11 | 2014-03-27 | Technion Research & Development Foundtion Limited | Anti-microbial peptides and uses of same |
| WO2016204841A1 (en) * | 2015-06-17 | 2016-12-22 | Avon Products, Inc. | Peptides and their use in the treatment of skin |
Non-Patent Citations (6)
| Title |
|---|
| Anishetty 등, BMC Structural Biology 2002, 2, available from: http://www.biomedcentral.com/1472-6807/2/9* |
| Banerji 등, J. Phys. Chem. B 2017, 121, 6367-6379* |
| Bauer 등, Biochemical and Biophysical Research Communications 406 (2011) 348―352* |
| Grewal 등, J. Phys. Chem. B 2004, 108, 4899―4908* |
| Hunt & Dayhoff, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS Vol. 39, No. 4, 1970, 757―765* |
| Krause 등, Inorg. Chem. 2010, 49, 362―364* |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190031182A (en) | 2019-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20140005110A (en) | Novel peptides and use thereof | |
| US10206969B2 (en) | Peptide for preventing or treating inflammatory diseases and use thereof | |
| KR102166930B1 (en) | Use of a peptide as a therapeutic agent for autoimmune disease or bone disease | |
| KR102166928B1 (en) | Use of a peptide as a therapeutic agent for autoimmune disease or bone disease | |
| KR102166927B1 (en) | Use of a peptide as a therapeutic agent for autoimmune disease | |
| KR102166929B1 (en) | Use of a peptide as a therapeutic agent for autoimmune disease | |
| US20240009264A1 (en) | Use of peptides as therapeutic agent for autoimmune diseases and bone diseases | |
| US20230234985A1 (en) | Use of peptides as therapeutic agent for autoimmune diseases and bone diseases | |
| KR102219928B1 (en) | Use of a peptide as a therapeutic agent | |
| KR102164417B1 (en) | Use of a peptide as a therapeutic agent | |
| KR102219926B1 (en) | Use of a peptide as a therapeutic agent | |
| KR20200062106A (en) | Use of a peptide as a therapeutic agent | |
| KR101655554B1 (en) | Pharmaceutical composition for prevention or treatment bone diseases comprising Alisma canaliculatum extract or fractions thereof, or compounds isolated from therefrom | |
| TW201710283A (en) | Inhibition of osteoclast formation | |
| WO2019054808A2 (en) | Use of peptides as therapeutic agent for autoimmune diseases and bone diseases | |
| US20190112337A1 (en) | Peptide for preventing or treating inflammatory diseases and use thereof | |
| WO2019054809A2 (en) | Use of peptides as therapeutic agent for autoimmune diseases and bone diseases | |
| KR20230110921A (en) | Pharmaceutical Composition comprising PKDCC for Preventing or Treating of Breast cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| N231 | Notification of change of applicant | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |